{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:13:18Z","timestamp":1772169198506,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HVTN Research and Mentorship Program"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2017.11.032","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T04:43:30Z","timestamp":1517978610000},"page":"1235-1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention"],"prefix":"10.1016","volume":"36","author":[{"given":"Arame","family":"Thiam-Diouf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Metch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robel","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Peake","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.11.032_b0005","doi-asserted-by":"crossref","DOI":"10.1007\/s10461-017-1736-3","article-title":"Drug use and sexual HIV transmission risk among men who have sex with men and women (MSMW), men who have sex with men only (MSMO), and men who have sex with women only (MSWO) and the female partners of MSMW and MSWO: a network perspective","author":"Dyer","year":"2017","journal-title":"AIDS Behav"},{"key":"10.1016\/j.vaccine.2017.11.032_b0010","first-page":"1","article-title":"Marijuana use and sex with multiple partners among lesbian, gay and bisexual youth: results from a national sample","author":"Zhang","year":"2017","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.vaccine.2017.11.032_b0015","article-title":"Substance use and sexual risk behavior among black South African men who have sex with men: the moderating effects of reasons for drinking and safer sex intentions","author":"Knox","year":"2016","journal-title":"AIDS Behav"},{"key":"10.1016\/j.vaccine.2017.11.032_b0020","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10461-012-0138-9","article-title":"HIV risk behaviors among Black\/African American and Hispanic\/Latina female partners of men who have sex with men and women","volume":"17","author":"Harawa","year":"2013","journal-title":"AIDS Behav"},{"key":"10.1016\/j.vaccine.2017.11.032_b0025","unstructured":"Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2015 National Survey on Drug Use and Health. HHS Publ No SMA 16-4984, NSDUH Ser H-51 n.d. <https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR1-2016\/NSDUH-FFR1-2016.htm> [accessed April 2017]."},{"key":"10.1016\/j.vaccine.2017.11.032_b0030","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/09540121.2013.772273","article-title":"Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States","volume":"25","author":"Pecoraro","year":"2013","journal-title":"AIDS Care"},{"key":"10.1016\/j.vaccine.2017.11.032_b0035","first-page":"459","article-title":"Effective strategies for maintaining research participation in clinical trials","volume":"43","author":"Zweben","year":"2009","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.vaccine.2017.11.032_b0050","unstructured":"Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Reports Morb Mortal Wkly Report Recomm Reports 2001;50:1\u201357; quiz CE1\u201319a1\u2013CE6\u201319a1. <https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5019a1.htm> [accessed November 2016]."},{"key":"10.1016\/j.vaccine.2017.11.032_b0040","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/QAD.0b013e328360c83e","article-title":"Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition: the step study NIH public access","volume":"17","author":"Novak","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2017.11.032_b0045","unstructured":"National Institute of Alcohol Abuse and Alcoholism. NIAAA council approves definition of binge drinking. NIAAA Newsl 2004; No 3, P 3 n.d. <https:\/\/pubs.niaaa.nih.gov\/publications\/AlcoholFacts&Stats\/AlcoholFacts&Stats.htm> [accessed November 2016]."},{"key":"10.1016\/j.vaccine.2017.11.032_b9000","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.vaccine.2017.11.032_b0055","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.addbeh.2014.04.006","article-title":"Binge drinking, stimulant use and HIV risk in a sample of illicit drug using heterosexual Black men","volume":"39","author":"Keen","year":"2014","journal-title":"Addict Behav"},{"key":"10.1016\/j.vaccine.2017.11.032_b0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10900-011-9418-y","article-title":"Prevalence of HIV risk behaviors between binge drinkers and non-binge drinkers aged 18-to 64-years in US, 2008","volume":"37","author":"Wen","year":"2012","journal-title":"J Community Health"},{"issue":"3","key":"10.1016\/j.vaccine.2017.11.032_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0000000000000974","article-title":"An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women","volume":"72","author":"Balkus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"10.1016\/j.vaccine.2017.11.032_b0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/OLQ.0b013e3181a9cc41","article-title":"Preduction of HIV acquisition among men who have sex with men","volume":"36","author":"Menza","year":"2009","journal-title":"Sexually Transmitted Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.11.032_b0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/QAI.0b013e318256b2f6","article-title":"Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States","volume":"60","author":"Smith","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.vaccine.2017.11.032_b0080","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/00224490209552198","article-title":"Recalling sexual behavior: a methodological analysis of memory recall bias via interview using the diary as the gold standard","volume":"40","author":"Graham","year":"2003","journal-title":"J Sex Res"},{"key":"10.1016\/j.vaccine.2017.11.032_b0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1521\/aeap.2016.28.5.417","article-title":"Social desirability response bias and other factors that may influence self-reports of substance use and HIV risk behaviors: a qualitative study in Vietnam","volume":"5","author":"Latkin","year":"2016","journal-title":"AIDS Educ Prev"},{"key":"10.1016\/j.vaccine.2017.11.032_b0090","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s10461-017-1792-8","article-title":"Social desirability bias and prevalence of sexual HIV risk behaviors among people who use drugs in Baltimore, Maryland: implications for identifying individuals prone to underreporting sexual risk behaviors","volume":"7","author":"Rao","year":"2017","journal-title":"AIDS Behav"},{"key":"10.1016\/j.vaccine.2017.11.032_b0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00281-006-0045-0","article-title":"Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy","volume":"28","author":"Ugen","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2017.11.032_b0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/CMR.16.2.209-219.2003","article-title":"Microbial infections, immunomodulation, and drugs of abuse","volume":"16","author":"Friedman","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.11.032_b0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1574-695X.2006.00097.x","article-title":"Addictive drugs and their relationship with infectious diseases","volume":"47","author":"Friedman","year":"2006","journal-title":"FEMS Immunol Med Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:59Z","timestamp":1759400699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17315967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X17315967"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}